Shares of Bausch Health Companies Inc (NYSE:BHC) have been assigned an average rating of “Hold” from the eleven research firms that are presently covering the stock, Marketbeat reports. Three analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $26.38.
Several brokerages have recently commented on BHC. HC Wainwright set a $25.00 price objective on shares of Bausch Health Companies and gave the stock a “hold” rating in a report on Monday, October 15th. ValuEngine upgraded shares of Bausch Health Companies from a “sell” rating to a “hold” rating in a report on Monday, September 24th. JPMorgan Chase & Co. upped their price objective on shares of Bausch Health Companies to $18.00 and gave the stock an “underweight” rating in a report on Wednesday, August 8th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $32.00 target price on shares of Bausch Health Companies in a research note on Tuesday, August 7th. Finally, Piper Jaffray Companies set a $16.00 target price on shares of Bausch Health Companies and gave the stock a “sell” rating in a research note on Tuesday, August 7th.
Shares of BHC stock opened at $22.85 on Monday. The company has a current ratio of 1.14, a quick ratio of 0.89 and a debt-to-equity ratio of 6.99. Bausch Health Companies has a one year low of $10.94 and a one year high of $28.45. The company has a market capitalization of $8.12 billion, a PE ratio of 5.97, a P/E/G ratio of 0.34 and a beta of -0.48.
In other news, CFO Paul Herendeen acquired 10,000 shares of the company’s stock in a transaction on Friday, September 14th. The shares were bought at an average cost of $22.61 per share, with a total value of $226,100.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Christina Ackermann sold 19,946 shares of the stock in a transaction that occurred on Tuesday, October 16th. The shares were sold at an average price of $24.98, for a total transaction of $498,251.08. The disclosure for this sale can be found here. Over the last three months, insiders acquired 165,000 shares of company stock worth $3,890,700. Insiders own 11.54% of the company’s stock.
Several large investors have recently made changes to their positions in BHC. Tobam purchased a new stake in shares of Bausch Health Companies in the 2nd quarter valued at approximately $13,886,000. Point View Wealth Management Inc. purchased a new stake in shares of Bausch Health Companies in the 2nd quarter valued at approximately $1,132,000. Private Management Group Inc. purchased a new position in shares of Bausch Health Companies in the 2nd quarter valued at $28,474,000. Van ECK Associates Corp purchased a new position in shares of Bausch Health Companies in the 2nd quarter valued at $11,494,000. Finally, Marshall Wace LLP purchased a new position in shares of Bausch Health Companies in the 2nd quarter valued at $2,974,000. 43.26% of the stock is currently owned by institutional investors.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Featured Article: Short Selling – Explanation For Shorting Stocks
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.